In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sally Ye

Latest From Sally Ye

Medtech Multinationals Up Pace Of Localization Strategies In China

China-specific go-to-market strategies are helping global medtechs access the fast-growing medical device market in China, where localization has become the buzzword for foreign players, writes news and analysis portal Omdia.

China Business Strategies

Beyond Lockdown: The Digitization Of Chinese Hospitals Continues Apace

The recent COVID-19 lockdown in Shanghai caused widespread disruption locally and an economic slowdown for China. But it did not interrupt the ongoing digitization of health care, the value of which was once again thrown into sharp relief, writes news and analysis portal Omdia.

China Policy

China’s Medtech Market Trends: Six Of The Best For 2022

The key health care and infrastructure trends in China and how they will affect the local medtech market and industry are listed by Medtech Insight’s sister news portal, Omdia.

China Policy

China Aims To Be Robotics Industry’s Global Innovation Center

China has released a five-year plan for the development of the robotics industry. Health care applications are a key part of that plan, according to reports from Omdia.

China Digital Health

China Targets Co-Pay Reductions Under National Medical Security Plan

China is making a renewed push to cover more people with health insurance, and says it will cut patients’ out-of-pocket contributions by a third and encourage more private insurance, according to reports from Omdia.

China Policy

Chinese Volume-Based Procurement Pilot Hits Medtech Stock Prices

The consequences of China’s volume-based, centralized procurement of medical supplies, initiated in 2018, are starting to become clear, according to reports from Omdia.

China Policy
See All
UsernamePublicRestriction

Register